Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo

British Journal of Cancer
|December 1, 1984
PubMed

Insights

Misonidazole (MISO) enhances DNA cross-linking by nitrogen mustard (HN2) in various mouse tissues, particularly liver and kidney. This potentiation is linked to MISO

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • DNA cross-linking agents like nitrogen mustard (HN2) are used in cancer therapy.
  • Misonidazole (MISO) is a hypoxic cell radiosensitizer.
  • Understanding drug interactions is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To investigate the effect of MISO on HN2-induced DNA cross-linking in vivo.
  • To determine tissue-specific variations in this interaction.
  • To explore the mechanisms underlying MISO's influence on DNA cross-linking.

Main Methods:

  • Alkaline elution technique for DNA cross-link analysis.
  • In vivo treatment of C3H mice with HN2 and MISO.
  • Tissue sample preparation 1 hour post-HN2 injection to assess initial cross-linking.

Main Results:

  • HN2 alone caused maximal cross-linking in spleen and jejunum, minimal in liver.
  • MISO pretreatment did not affect cross-linking in spleen and jejunum.
  • MISO significantly enhanced HN2-induced cross-linking in liver (6-fold) and kidney (3.1-fold).
  • Potentiation correlated with MISO-induced GSH depletion and macromolecular binding, suggesting nitroreduction-dependent mechanisms.

Conclusions:

  • MISO potentiates HN2-induced DNA cross-linking in a tissue-specific manner.
  • The enhancement is likely mediated by nitro-reduced MISO metabolites.
  • These findings have implications for combination therapies involving MISO and DNA cross-linking agents.

Related Concept Videos